AIT Laboratories, a HealthTrackRx company, is a leading clinical solutions company that strives to improve health outcomes and patient care by assisting providers to mitigate risk in treating substance use disorder through prevention, testing, and compliance.
SureTestRx™ - Our Proprietary Methodology
SureTestRx is our solution for physicians, payers, and patients. Using this testing method, you can remove the ambiguity of guessing what is in a patient’s system and ensure medical necessity by only confirming the pertinent positive and negative screen results.
Ordering compliance monitoring testing can be confusing for physicians and is generally guided by treatment and medication lists – while frequently overlooking illicit medications and drugs that are not identified by patients.
Our SureTestRx methodology simplifies test-ordering for providers, minimizes costs for payers, ensures only medically necessary definitive testing performed, and maximizes the value of clinical data for patient treatment. Given the diversity of patients, it is imperative that physicians “Know what you are looking for.“
Ordering compliance monitoring testing in urine or oral fluids can be confusing for physicians and is generally guided by treatment and medication lists; in addition, test ordering may overlook illicit medications and drugs not identified by patients.*
Physicians are essentially guessing what is in a patient’s system when ordering drug testing.
Current solutions are not working. According to the CDC, the opioid epidemic has not plateaued in 15 years, drug poisoning has killed more people than guns and car accidents.
When fewer drug classes are screened based on limitations of technology, there is an increase in the number of definitive confirmation tests required.
The result is the payers are picking up the majority of costs for treatment of chronic opioid use and abuse treatment.
- 1,189% increase in alcohol and/or drug claims from 2011 to 2014.
- 848% increase in laboratory testing for patients with opioid diagnosis.
Testing should be simple and affordable.
Our SureTestRx solution increases the number of drug classes that can be identified during the screening process and lowers the number of definitive confirmation tests required – which lowers the cost for patients and payers. This also simplifies test-ordering for providers, ensures only medically necessary definitive testing is performed, and maximizes value of clinical data for patient treatment.
The Impact of Technology
SureTestRx vs. EIA (Enzyme ImmunoAssay) Testing
When fewer drug classes are subject to a presumptive screen, the number of CPT and G codes billed for definitive confirmation is higher, thus increasing costs for patients and payers.
SureTestRx 30 drug class screen reflex to confirmation provides accurate and specific information that provides the following benefits:
- simplifies how all physicians order tests, regardless of specialty or patient type
- provides maximum data to cover all diagnoses but only as medically necessary
- minimizes number of test confirmations reported
- contains costs for payers and makes bills affordable for patients
CMS guidelines state the following: Perform presumptive screen for all listed drug classes and confirm only those drug classes that are medically necessary.
** In a sample size of 6,000 – 38% of samples contained one or more drugs not prescribed by the treating physician or identified by patients. Physicians had not ordered tests for these drugs and therefore did not have the data for treatment.